Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. LYEL | 0.00 |
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:
LYEL) with a Buy and maintains $44 price target.
